Nordson Corporation (NDSN) Q4 2025 Financial Results Summary
QuoteReporter
•4 min read
Nordson Corporation (NDSN) Q4 2025 Financial Results Summary
On December 10, 2025, Nordson Corporation (Nasdaq: NDSN) reported its financial results for the fourth quarter and full fiscal year ended October 31, 2025.
Key Financial Metrics for Q4 2025:
- Sales: $752 million, representing a 1% increase compared to $744 million in Q4 2024.
- Sales Drivers:
- 2% favorable currency translation.
- 1% contribution from acquisitions.
- Offset by: A divestiture in the medical contract manufacturing sector and a 1% organic sales decrease.
- Net Income: $152 million, or $2.69 per diluted share, compared to $122 million ($2.12 per share) in Q4 2024.
- Adjusted Net Income: $171 million, up from $160 million year-over-year.
- Adjusted Earnings per Share: $3.03; a 9% increase from $2.78 in the prior year.
- EBITDA: $256 million, accounting for 34% of sales, a 6% increase from $241 million (32% of sales) in Q4 2024.
Fourth Quarter Segment Results:
- Industrial Precision Solutions:
- Sales: $362 million; decreased by 2% from $370 million.
-
EBITDA: $137 million (38% of sales), up 1% from $136 million (37% of sales).
-
Medical and Fluid Solutions:
- Sales: $220 million; increased by 10% from $200 million.
-
EBITDA: $88 million (40% of sales), a margin improvement of 380 basis points from 36%.
-
Advanced Technology Solutions:
- Sales: $171 million; decreased by 4% from $177 million.
- EBITDA: $43 million (25% of sales), down from $48 million (27% of sales).
Full Year 2025 Results:
- Record Sales: $2.8 billion, reflecting a 4% increase over the previous year.
- Net Income: $484 million, or $8.51 per diluted share, compared to $467 million ($8.11 per share) in FY 2024.
- Adjusted Earnings per Share: $10.24, a 5% increase from $9.73.
- EBITDA: $900 million, maintaining 32% of sales, compared to $849 million (32% of sales) from the prior year.
- Free Cash Flow: $661 million, a record amount, indicating a conversion rate of 136% of net income.
Fiscal 2026 Guidance:
- Forecasted Sales: Expected to range between $2.83 billion and $2.95 billion.
- Adjusted Earnings Guidance: Projected in the range of $10.80 to $11.50 per diluted share.
Shareholder Value Initiatives:
- Dividends Paid: $179 million during FY 2025, an increase from $161 million in FY 2024.
- Share Repurchases: Ongoing repurchase activities were noted, reflecting a continued commitment to returning value to shareholders.
Strategic Highlights:
- Fourth quarter EBITDA margin achieved record levels with a free cash flow conversion rate of 128%.
- Successfully completed the divestiture of the medical contract manufacturing business on September 2, 2025.
- Operational excellence noted as a strength amidst macroeconomic challenges.
Closing Remarks:
Nordson Corporation’s quarterly results underscore robust performance in segments like Medical and Fluid Solutions while navigating challenges in Industrial Precision and Advanced Technology Solutions. The fiscal outlook remains optimistic with solid forecasts for sales and earnings, backed by a proactive capital allocation strategy aimed at enhancing shareholder value through dividends and share buybacks.
Management will elaborate on these results and future outlook in a webcast scheduled for December 11, 2025.
| Three Months Ended | Twelve Months Ended | |||
|---|---|---|---|---|
| October 31, 2025 | October 31, 2024 | October 31, 2025 | October 31, 2024 | |
| Sales | $751,820 | $744,482 | $2,791,687 | $2,689,921 |
| Cost of sales | 328,353 | 341,658 | 1,251,903 | 1,203,792 |
| Gross profit | 423,467 | 402,824 | 1,539,784 | 1,486,129 |
| Gross margin % | 56.3 % | 54.1 % | 55.2 % | 55.2 % |
| Selling & administrative expenses | 208,872 | 223,932 | 815,514 | 812,128 |
| Divestiture and related charges | 334 | — | 12,545 | — |
| Operating profit | 214,261 | 178,892 | 711,725 | 674,001 |
| Interest expense – net | -23,770 | -27,282 | -101,105 | -84,011 |
| Other expense – net | -7,592 | -3,538 | -12,972 | -4,509 |
| Income before income taxes | 182,899 | 148,072 | 597,648 | 585,481 |
| Net Income | $151,634 | $122,168 | $484,474 | $467,284 |
| Weighted-average common shares outstanding: Basic | 56,077 | 57,188 | 56,606 | 57,176 |
| Diluted | 56,417 | 57,603 | 56,916 | 57,616 |
| Earnings per share: Basic earnings | $2.70 | $2.14 | $8.56 | $8.17 |
| Diluted earnings | $2.69 | $2.12 | $8.51 | $8.11 |
| October 31, 2025 | October 31, 2024 | |
|---|---|---|
| Cash and cash equivalents | $108,442 | $115,952 |
| Receivables – net | 587,843 | 594,663 |
| Inventories – net | 444,814 | 476,935 |
| Other current assets | 101,752 | 87,482 |
| Total current assets | 1,242,851 | 1,275,032 |
| Property, plant & equipment – net | 516,914 | 544,607 |
| Goodwill | 3,304,685 | 3,280,819 |
| Other assets | 853,231 | 900,508 |
| Notes payable and debt due within one year | $315,000 | $103,928 |
| Accounts payable and accrued liabilities | 443,260 | 424,549 |
| Total current liabilities | 758,260 | 528,477 |
| Long-term debt | 1,681,254 | 2,101,197 |
| Other liabilities | 434,596 | 439,100 |
| Total shareholders’ equity | 3,043,571 | 2,932,192 |